New DNA vaccine aims to clear Cancer-Causing HPV

NCT ID NCT06210854

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This phase 2 trial tests a DNA vaccine called pBI-11 in 48 women with persistent HPV16 or HPV18 cervical infection. The vaccine is designed to boost the immune system to clear the virus. Participants receive the vaccine or a placebo via injection with a special device. The study focuses on safety and whether the virus disappears.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pBI-11 DNA vaccine
What this could lead to: If successful, this vaccine could help clear persistent HPV16/18 infections, reducing the risk of cervical cancer.
What could go wrong: This is an early phase 2 trial with only 48 participants, so results may not apply widely. The vaccine may not clear the virus or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV INFECTION

Contacts and locations

Locations

Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States
University of Alabama at Birmingham
NOT_YET_RECRUITING

Birmingham, Alabama, 35249, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.